



Sensipar® (cinacalcet) – New warning

- On May 23, 2017, the [FDA approved](#) an update to the *Warnings and Precautions* section of the [Sensipar \(cinacalcet\)](#) drug label regarding hypotension, worsening heart failure (HF) and/or arrhythmias.
- Sensipar is indicated for the treatment of: secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis, hypercalcemia in adult patients with parathyroid carcinoma, and hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.
 - Sensipar is not indicated for use in adult patients with CKD who are not on dialysis because of an increased risk of hypocalcemia.
- In post marketing safety surveillance, isolated, idiosyncratic cases of hypotension, worsening HF, and/or arrhythmia have been reported in patients with impaired cardiac function, in which a causal relationship to Sensipar could not be completely excluded and which may be mediated by reductions in serum calcium levels.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.